Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.

[1]  J. Bruix,et al.  BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.

[2]  H. Koga,et al.  Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  M. Luu,et al.  Decreasing trend of serum alpha-fetoprotein level in hepatocellular carcinoma. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  A. Noufaily,et al.  Role of methylated septin 9 as an adjunct diagnostic and prognostic biomarker in hepatocellular carcinoma. , 2021, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[5]  M. Otsuka,et al.  Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma , 2021, Journal of Gastroenterology.

[6]  Hongyi Liu,et al.  Opportunistic screening and survival prediction of digestive cancers by the combination of blood mSEPT9 with protein markers , 2020, Therapeutic advances in medical oncology.

[7]  H. Shiraha,et al.  Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA , 2020, Journal of gastroenterology and hepatology.

[8]  A. Lok,et al.  Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: a Systematic Review. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  H. Nagano,et al.  Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma , 2020, Hepatology communications.

[10]  M. Kudo,et al.  Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma , 2019, Liver Cancer.

[11]  M. Kudo,et al.  Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[12]  K. Yoon,et al.  Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib , 2019, BMC Cancer.

[13]  J. Bruix,et al.  Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. , 2018, Journal of hepatology.

[14]  A. Ayav,et al.  Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma , 2018, EBioMedicine.

[15]  Y. Suehiro,et al.  Blood free-circulating DNA testing by highly sensitive methylation assay to diagnose colorectal neoplasias , 2018, Oncotarget.

[16]  Qi Zhao,et al.  Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. , 2017, Nature materials.

[17]  Chia-Yang Hsu,et al.  Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. , 2016, European journal of cancer.

[18]  G. Spolverato,et al.  Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma , 2016, PLoS medicine.

[19]  Chia-Yang Hsu,et al.  Using Serum α-Fetoprotein for Prognostic Prediction in Patients with Hepatocellular Carcinoma: What is the Most Optimal Cutoff? , 2015, PloS one.

[20]  P. Hurban,et al.  Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. , 2014, Clinical chemistry.

[21]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[22]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[23]  P. Tangkijvanich,et al.  Clinical Characteristics and Prognosis of Hepatocellular Carcinoma: Analysis Based on Serum Alpha-fetoprotein Levels , 2000, Journal of clinical gastroenterology.

[24]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.